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KESAN 2-METOKSI-1,4-NAFTOKUINON (MNQ) DALAM METABOLISME 
GLUKOSA SEL-SEL MDA-MB-231 
 
ABSTRAK 
Kuinon dan bahan terbitannya telah menunjukkan aktiviti biologi dan sifat 
perubatannya termasuk antikulat, antibakteria dan antikanser. Sehingga kini, para 
penyelidik telah memfokuskan sasaran ubat kemoterapi terhadap gen atau protein/enzim 
yang spesifik dalam metabolisme kanser. Kajian ini menggunakan 2-metoksi-1,4-
naftokuinon (MNQ) berdasarkan peningkatan laporan kesan perubatannya dalam 
mendorong kematian sel kanser. Kajian ini bertujuan untuk menilai kesan MNQ dalam 
metabolisme glukosa kanser payudara tigaan negatif, sel-sel MDA-MB-231. Pada 
permulaannya, sel-sel MDA-MB-231 dirawat dengan pelbagai dos MNQ untuk 
menentukan kesan perencatan pertumbuhan dan dos IC₅₀. Kesan MNQ juga telah diuji 
di dalam sel-sel epitelium payudara bukan malignan, MCF10A. Untuk analisis lanjutan, 
sel-sel MDA-MB-231 telah dirawat dengan MNQ pada dos IC₅₀ untuk pengukuran 
pengambilan glukosa, penghasilan laktat serta pengekspresan molekul yang terlibat 
dalam glikolisis (GLUT1, Akt, HKII dan HIF1α). Kesan MNQ juga telah diuji pada 
aktiviti autofagi dan pengekpresan gen yang terlibat dengan autofagi (Beclin 1 dan 
LC3).  Hasil kajian menunjukkan bahawa MNQ menyekat pertumbuhan sel-sel MDA-
MB-231 dengan nilai IC₅₀ 43, 29 dan 22 μM (24, 48 dan 72 j rawatan) tetapi tidak pada 
sel-sel MCF10A. MNQ juga menyekat aktiviti glikolitik pada sel-sel MDA-MB-231 
melalui perencatan pengambilan glukosa dan pengurangan penghasilan laktat. 
Penurunan pengawalaturan  GLUT1 dan Akt pada kedua-dua gen dan protein di dalam 
xiv 
 
sel-sel MDA-MB-231 menunjukkan bahawa perencatan glikolisis oleh MNQ adalah 
melalui perantaraan isyarat laluan GLUT1/Akt. Peningkatan pengekspresan gen HKII, 
Beclin 1, LC3 dan pembentukan autofagosom di dalam sel-sel MDA-MB-231 
menunjukkan MNQ mengaruh aktiviti autofagi. Perencatan pengambilan glukosa ke 
dalam sel-sel mungkin menyebabkan kekurangan nutrien lalu mengaktifkan autofagi di 
dalam sel-sel MDA-MB-231. Sebagai kesimpulan, kebolehan MNQ untuk menghalang 
glikolisis melalui sasaran ke atas molekul yang terlibat dengan glikolisis di dalam sel-sel 
kanser payudara tigaan negatif (MDA-MB-231), mencadangkan potensi MNQ sebagai 






THE EFFECTS OF 2-METHOXY-1,4-NAPHTHOQUINONE (MNQ) ON 
GLUCOSE METABOLISM OF MDA-MB-231 CELLS 
 
ABSTRACT 
Quinone and its derivatives are shown to have biological activities and medicinal 
properties including antibacterial, antifungal as well as anticancer activities. To date, the 
researchers have been focusing on targeting the chemotherapeutic drugs at the specific 
genes or proteins/enzymes of cancer metabolism. In this study, 2-Methoxy-1,4-
Naphthoquinone (MNQ) was selected based on the increasing reports of its medicinal 
effects in promoting cancer cells death. The aim of this study is to evaluate the effects of 
MNQ on glucose metabolism in triple-negative breast cancer, MDA-MB-231 cells. 
Initially, the MDA-MB-231 cells were treated with various doses of MNQ to determine 
the growth inhibitory effects and the IC50 dose. The effect of MNQ on cell growth was 
also tested in non-malignant breast epithelial cells, MCF10A. For further analyses, the 
cells were treated with IC50 dose of MNQ for measurement of glucose uptake, lactate 
production as well as the expression of glycolysis-related molecules (GLUT1, Akt, HKII 
and HIF1). The effect of MNQ was also tested on the autophagy activities and the 
expression of autophagy-related genes (Beclin 1 and LC3). The results showed that 
MNQ inhibited the proliferation of MDA-MB-231cells with IC₅₀ values of 43, 29 and 
22 μM (24, 48 and 72 h of treatment) but not in MCF10A cells. MNQ also inhibited the 
glycolytic activities in MDA-MB-231 cells by inhibiting the glucose uptake and 
reducing the lactate production. The down-regulation of GLUT1 and Akt in both gene 
and protein expression of MDA-MB-231 cells suggested that inhibition of gycolysis by 
xvi 
 
MNQ was mediated by GLUT1/Akt signaling pathways.  Increased HKII, Beclin 1 and 
LC3 gene expression as well as the formation of autophagosomes in MDA-MB-231 
cells showed that MNQ induced the autophagy activity. The inhibition of glucose uptake 
into the cells may cause the nutrient deprivation and lead to the activation of autophagy 
in MDA-MB-231 cells.  In conclusion, the ability of MNQ to inhibit glycolysis by 
targeting the glycolysis-related molecules in triple-negative breast cancer cells (MDA-









INTRODUCTION AND LITERATURE REVIEWS 
1.1 Cancer 
Cancer is a class of disease characterized by uncontrolled cell proliferation and has the 
ability to spread throughout the whole body. Cancer that grows locally known as benign 
tumor, whereas the other one, malignant tumor can invade and spread into nearby tissues 
and the process is known as metastasis (Sudhakar, 2009, Baskar et al., 2014). Cancer 
cells are formed due to the modification or mutation of the DNA of the normal cells, 
either by spontaneous or induced by environmental factors such as radiation, chemicals 
and microorganisms. Cancer cells continue to develop if the body immune system is not 
functioning properly and  worse under certain condition such as unhealthy environment, 
poor diet and people at an advanced age (Sharma et al., 2010). 
1.1.1 Overview of cancer incidence 
The most common cancers in both men and women are lung, followed by breast, 
colorectal and prostate cancer. Cancer is the second leading cause of death worldwide, 
and the numbers are expected to increase more than two times in the next 20-40 years, 
surpass the current leading cause of death, heart disease (Bray et al., 2018, Jemal et al., 
2010, Thun et al., 2009, IARC, 2018). In 2018, an estimated 18.1 million new cancer 
cases and 9.6 million cancer deaths were recorded worldwide, which lung cancer, 
leading the number with a total of 11.6 % of cancer diagnosed and 18.4 % cancer death 
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(Bray et al., 2018, IARC, 2018) (Figure 1.1). International Agency for Research on 
Cancer (IARC) has projected that by the year 2030, about 26 million new cases and 17 
million of death caused by cancer will occur each year all over the world (IARC, 2018).  
1.1.2 Cancer incidence in Malaysia 
Asia is a diverse continent and accounts for 60 % of global population (Bray et al., 
2018).  Most Asian countries are still developing except for high-income countries 
(HICs) such as Japan, Hong Kong, South Korea, Singapore, United Arab Emirates, 
Kuwait, Qatar, Saudi Arabia and Bahrain. The majority of the population in Asia is 
grouped as low and middle-income countries (LMICs) for example India, Philippines, 
Thailand and including Malaysia. Consequence of the diverse economic development 
and investment in HICs and LMICs, Asian countries have highly variable health service 
development and healthcare infrastructure (Sankaranarayanan et al., 2014). Compared to 
HICs, most LMICs have poor, limited health services and the cancer burdens are 
significant in these areas. Other than that, increasing urbanization, changing lifestyle, 
obesity, diet and increasing lifespan also contribute to the increasing cancer burden and 
changing cancer pattern in different regions of Asia (Forman et al., 2014, 
Sankaranarayanan et al., 2014, Długosz and Raźniak, 2014). 
Asia accounts for almost half of the cancer burden which is 48.4 % of cancer cases with 
estimated 8.7 million, whereas 5.4 million deaths (57.3 %) in 2018. More than 70 % of 
the cancer deaths were reported to occur in LMICs. These incidences of cancer cases 
and cancer deaths are estimated to increase continuously to over 10.7 million and 7.5 




Figure 1.1 Estimated number of new cases in 2018 both in men and women worldwide  
Over 18 million new cancer cases were estimated in 2018 both in men and women 
worldwide with lung cancer recorded the highest cases followed by breast, colorectum, 




In Malaysia, 103,507 new cancer cases and 64,275 cancer deaths were reported in the 
year of 2007-2011, which increased by fivefold from data recorded in 2003 (21,464 
cancer cases) according to the National Cancer Institute (NCI, 2016). In 2018, breast 
cancer is the most common cancers diagnosed in Malaysia which accounts for 17.3 % of 
new cancer cases (7,953) and 11.0 % of cancer death (2,894) both in men and women 
(IARC, 2018).  
1.2 Breast cancer 
Cancer is named according to the body part in which the cancer originated. For example, 
sarcomas are cancer from muscle and connective tissue, whereas carcinomas are cancers 
derived from epithelial cells (Alberts et al., 2007, Heidari, 2019). Thus, breast cancer 
refers to the uncontrolled growth of the cells that originate from breast tissue, most 
commonly from the inner lining of the milk ducts or the lobules that supply the ducts 
with milk (Sharma et al., 2010). Breast cancer is the most frequently diagnosed life-
threatening cancers and most common cause of cancer death in women worldwide. In 
2018, almost 2.1 billion new cases of breast cancer were reported in both men and 
women, and nearly 627,090 of death occurred due to breast cancer worldwide (IARC, 
2018).  
1.2.1 Risk factors for developing breast cancer 
There are many factors that can contribute to cancer development. Generally, cancers 
are caused by dietary habits, lifestyle and environmental factors (Kamińska et al., 2015, 
Sun et al., 2017). Breast cancer is believed to be caused by a single or a combination of 
intrinsic (age, sex, familial susceptibility and hormonal changes) and extrinsic (dietary 
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habits, physical activity) factors. Among all, age and female sex have been considered as 
a major risk for developing breast cancer where it was frequently observed in women at 
menopausal age. The incidence of breast cancers was recorded higher among women 
between 40 and 59 years and it reaches a plateau in women at age more than 70 
(Kamińska et al., 2015). Besides, breast cancer also is a type of cancer that is closely 
associated to the hormonal status in the body. Thus, the chances of women getting breast 
cancer are higher compared to men due to the cumulative lifetime exposure to estrogen, 
such as puberty, pre-menopausal monthly cycles, pregnancy and breastfeeding (Davis 
and Lin, 2011, Key et al., 2013). It was also reported that breast cancer incidence is due 
to genetic heredity factors and related to family history. Women who had a first degree 
relative with breast cancer have higher risk of developing breast cancer compared to 
women without any affected relative (Brewer et al., 2017). The inherited susceptibility 
to the breast cancer is partially attributed to the mutations of breast cancer related genes 
such as BRCA1 and BRCA2 (Sun et al., 2017).  
1.2.2 Types of breast cancer 
The compositions of the breast are mainly from the two types of tissues which are 
glandular tissues and stromal tissues. Glandular tissues contain milk-producing glands or 
known as lobules and ducts. Meanwhile, stromal tissues is composed of fatty and fibrous 
connective tissues to support the breast (Sharma et al., 2010) (Figure 1.2). Breast cancer 
has been grouped into different subgroups based on the histological appearance, stage, 
tumor grade, lymph node status and molecular profiles. The heterogeneity of breast 
cancer makes diagnosis and treatment become more challenging (Holliday and Speirs, 




Figure 1.2 The structure of breast 
Breast cancer usually develops from the inner lining of milk duct or the lobules that 
supply the ducts with milk. Ductal carcinoma refers to breast cancer originating from 
ducts and those originating from lobules are known as lobular carcinoma. (Extracted 








In general, breast cancer can be broadly classified into 2 types; carcinoma in situ and 
invasive carcinoma (Table 1.1).  
All carcinomas are grouped as ductal and lobular based on the site from which the tumor 
arises. For example, cancers originating from the ducts are referred as ductal 
carcinomas, whereas those originating from the lobules are referred as lobular 
carcinomas (Makki, 2015, Nounou et al., 2015). 
Carcinoma in situ is classified as either ductal (ductal carcinoma in situ) DCIS or 
lobular (lobular cancer in situ) LCIS. DCIS often found in the mammary duct, while 
LCIS arise from atypical lobular hyperplasia. Both in situ carcinomas arise from atypical 
proliferation of cells and do not invade normal tissue, thus they cannot cause serious 
morbidity unless they become invasive (Logan et al., 2015). 
Invasive carcinoma refers to malignant abnormal proliferation of neoplastic cell in the 
breast tissue, which has penetrated through the duct wall into stroma. The major invasive 
tumor types include invasive ductal carcinoma (IDC) or invasive lobular carcinoma 
(ILC). The IDC is the most common type of breast cancer and accounts for 70-80 % of 
breast cancer incidence reported (Lester et al., 2009). Most of the breast malignancies 
are adenocarcinoma, which constitutes more than 95 % of breast cancers (K et al., 
2010). 
1.2.3 Molecular classification of breast cancer 
Study by Perou et al. (2000) has classified breast cancer into the subgroups according to 
the similarities in the gene expression profiles using the microarray technique. This 
classification technique was widely accepted by the medical and scientific community  
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Table 1.1 Types of breast cancer (Adapted from Makki, 2015 and Nounou et al., 2015). 
Types of breast cancer Description 
Ductal carcinoma in situ (DCIS) Begin inside the milk ducts of the breast and do not 
spread to other area. 
Lobular carcinoma in situ (LCIS) Drastic increase in the number of cells within the 
lobules of the breast and do not spread to other area. 
Invasive ductal carcinoma (IDC) Begin in the milk ducts of the breast and penetrates 
the wall of the duct, invading the fatty tissues of the 
breast and possibly other regions of the body. The 
most common types of breast cancer, accounting for 
80 % of breast cancer diagnosis. 
Invasive lobular carcinoma (ILC) Begin in the milk glands (lobules) of the breast, but 
spread to other regions of the body. Account for 10-




with the hope that this technique will provide a new insight into the biology of breast 
cancer, thus determine a variety of therapeutics approach in targeting breast cancer. The 
classification of breast cancers is categorized based on the gene signature of estrogen 
receptor (ER), progesterone-receptor (PR) and human epidermal growth factor receptor 
2 (HER2) (Tang and Tse, 2016) as summarised in Table 1.2. 
Luminal A 
Luminal A is characterised by ER/PR positive and HER2 negative. It includes a wide 
range of low-grade variants and account for 50 % of invasive breast cancer. Luminal A 
basically has a good prognosis for treatment (Inic et al., 2014). 
Luminal B 
Luminal B is the ER/PR positive and HER2 is variable (positive or negative). The 
proliferation rate and histological grades are higher than luminal A, which moderate 
expression of hormone receptor and associated genes. This category account 20 % of 
invasive breast cancer diagnosed and the response to the therapy is variable. Luminal B 
prognosis is lower compared than luminal A (Inic et al., 2014). 
HER2 overexpression 
HER2 overexpression is ER/PR negative, but HER2 strong positive. This tumor is more 
likely to be of high grade, particularly aggressive and more likely to spread rapidly than 
other types of breast cancer. This group of breast cancer compromises 15 % of all 
invasive breast cancer and implies poor prognosis. It was shown to have the highest 
sensitivity against trastuzumab (herceptin) therapy (Logan et al., 2015).  
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Table 1.2 Classification of breast cancer based on molecular expression (Adapted from 
Holliday and Speirs, 2011). 
 
Classification  
ER PR HER2 Other characteristics  
Luminal A Positive  Positive/
Negative 








Positive Ki67 high, usually endocrine 













Negative Negative Negative EGFR
+
 and/or cytokeratin 
5/6
+
, Ki67 high, endocrine 
nonresponsive, often 
chemotherapy responsive 
Claudin low Negative Negative Negative Ki67, E-cadherin, claudin-3, 
claudinin-4 and claudinin-7 






Basal-like breast cancer 
The basal-like breast cancers are named according to its pattern that is similar to the 
basal epithelial cells. It is ER/PR negative and HER2 negative (triple negative) and 
referred to triple-negative breast cancer (TNBC). TNBC cell lines are highly aggressive, 
metastatic and typically lack expression of the molecular targets that confer 
responsiveness to highly effective targeted therapies such as tamoxifen or trastuzumab. 
It has generally poor prognosis and compromises about 15 % of all invasive breast 
cancers (Toft and Cryns, 2011). 
Claudin low 
Claudin low is a more recently added class with triple negative (ER, PR and HER2). 
However, only a minority of TNBC are Claudin low. This subtype was distinct to basal 
like by the low expression of cell-cell junction protein, including claudins 3, 4, 7, and E-
cadherin (Herschkowitz et al., 2007, Nounou et al., 2015).  
1.2.4 Stages of breast cancer 
Since 2018, the stages of breast cancers are determined according to the updated staging 
guidelines by American Joint Committee on Cancer (AJCC). Considering the additional 
information on the tumor grade, ER, PR, and HER2 status have made determining the 
stage of breast cancer more complicated, but also more accurate.  The stages of breast 
cancer are expressed in the Roman numerals, starting from stage 0-IV. Stage 0 is 
considered as non-invasive or in situ cancer stage, whereas I is the (invasive) least 
advanced stage and continue with stage II, III and IV with more advanced stages as 
listed in Table 1.3. 
12 
 
Table 1.3 Stages of breast cancer (Adapted from 
https://www.breastcancer.org/symptoms/diagnosis/staging#stage0). 
 
Stage  Tumor grade ER PR HER2 
0 
 
DCIS; cancer cells do not invade 
neighboring tissues 
None  None  None 
I 
 
IA The tumor size > 2 cm 
Not spread outside the breast 
No lymph nodes involved 
Positive Positive   Negative  
IB No tumor in breast 
Tumor between 0.2 mm to 2 mm- found 
in lymph nodes, or 
Tumor in breast < 2 cm 
Tumor between 0.2 mm to 2 mm-found 
in lymph nodes 
Negative Negative  Negative  
II 
 
IIA No tumor in breast 
Tumor > 2 mm found in 1-3 axillary 
lymph nodes or lymph nodes near the 
breast bone, or 
Tumor < 2 cm has spread to the axillary 
lymph nodes, or 
Tumor between 2 cm-5 cm and has not 
spread to the axillary lymph nodes 
Negative Positive  Positive  
IIB Tumor in breast between 2 cm-5 cm 
Tumor between 0.2 mm to 2 mm-found 
in the lymph nodes, or 
Tumor between 2 cm-5 cm has spread to 
1-3 axillary lymph nodes, or 
Tumor > 5 cm but has not spread to 
axillary lymph nodes 




Table 1.3 continued 
III 
 
IIIA No tumor in breast 
Tumor is found in 4-9 axillary lymph 
nodes, or 
Tumor > 5 cm 
Tumor between 0.2 mm-2 mm-found in 
lymph nodes, or 
Tumor > 5 cm 
Tumor has spread to 1-3 axillary lymph 
nodes 
Negative  Negative  Negative  
IIIB Tumor may be any size has spread to the 
chest and caused swelling or ulcer, and  
May spread to 9 axillary lymph nodes 
Negative Negative Negative 
IIIC Reddening around breast area 
Breast feels warm and swollen 
Cancers have spread to the lymph nodes 
Negative  Negative  Positive  
IV 
 
Metastatic breast cancer; invasive breast 
cancer that has spread beyond breast area 
and nearby lymph nodes to the other 
organs of the body 




 1.2.5 Breast cancer management 
In recent years, many treatment and management options exist for cancer patients and 
resulted in wide variations in the survival and mortality among breast cancer patients in 
different countries and population worldwide. Many factors influenced these variations 
such as breast cancer awareness, early detection, intervention, better medical therapies 
and improved surgical techniques. Despite these factors, breast cancer remains the most 
common cancer cause of death from cancer in women worldwide (Hortobagyi et al., 
2005, Kingston and Johnston, 2016). 
Screening mammography has been recorded as the greatest contribution to early 
detection and decrease in breast cancer mortality. Mammography is the preferred 
screening examination for detecting abnormality of the breast before it can be felt by the 
woman herself or her physician. The patient feels a breast lump when breast cancer has 
grown to the point where physical symptoms and signs appear. Mammography is widely 
available, well-tolerated and the price for the test are affordable (Løberg et al., 2015). 
Once breast cancer is diagnosed and localized, a stage is assigned to it based on how 
advanced it is. The stage and site of breast cancer determine the appropriate treatment 
and the prognosis. There are several options for breast cancer treatments including 
surgery, radiotherapy, chemotherapy, and gene therapy (Cristofanilli et al., 2003, Akram 
et al., 2017). 
Surgery 
The first step and the most common treatment of breast cancer is surgery. It involves 
removing the tumor and the surrounding tissues that might be cancerous, known as 
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margin. There are two types of surgery in breast cancer treatment, which are removal of 
the lump only (lumpectomy) and surgical removal of the entire breast (mastectomy) 
depending on the stage and type of tumor. The goal during breast cancer surgery is to 
make sure the tissue removed has margins that are clear from tumor, indicating the 
cancer has been fully excised. Otherwise, further surgery to remove left over tissue may 
be required (Bellavance and Kesmodel, 2016, Akram et al., 2017).  
Chemotherapy 
Chemotherapy is the treatment of cancerous cells by using anti-cancer drugs. 
Chemotherapy is often given in cycles of treatment, recovery and treatment again. 
Selection of which patients are eligible for chemotherapy is based on overall health, age, 
medical history, type, stage of cancer and patient tolerance for specific medications. 
Chemotherapy can also be given before surgery to shrink the tumor and make breast 
conserving surgery possible compared to mastectomy (Lopez et al., 2008, Anampa et al., 
2015). 
Radiotherapy 
Radiotherapy involves radiation, such as x-rays or gamma rays that target tumor 
directly. This treatment is usually performed after surgery and is very effective in killing 
cancer cells that remain after surgery. Usually, the dose of radiation used must be 
powerful enough to ensure the cancer cells can be eliminated. Treatment using 






Gene therapy is one of the most recent treatments involved in the management of breast 
cancer. Gene therapy is an experimental technique that uses gene(s) to treat or prevent 
disease. Based on the study of cancer arised due to the accumulation of genetic 
modification, gene therapy was considered as a newly potential therapy to inhibit cancer 
cells. This technique allows doctors to treat cancer by inserting a gene of interest into a 
patient’s cells. There are several approaches applied by the researchers in gene therapy 
such as replacing a copy of the mutated gene with a healthy gene, inactivating a mutated 
gene and inserting a new gene to prevent or treat a disease in the body. The clinical 
studies of gene therapy on breast cancer were generally well-tolerated, with a few side 
effects reported. For example, treatments of transgene using a designed oncolytic viruses 
as a vector to the six patients with recurrent breast cancer decreased tumor size up to 30-
100 % (Kimata et al., 2006, Love and Uy, 2008, McCrudden and McCarthy, 2014).  
1.3 Cancer cell metabolism 
Normal cells are equipped with complex and systematic signaling network that are 
coordinated by key control enzymes, operating metabolic machineries and sensing 
environmental signals to provide sufficient energy for survival. They are expected to 
grow, divide and die in a perfectly controlled manner (Jang et al., 2013). However, 
cancer cells exhibit different metabolic requirements and altered metabolic activities 
compared from those of normal cells. Altered energy metabolism is associated with 
increased metabolism of glucose, protein and lipid in cancer cells (Fadaka et al., 2017). 
These alterations in metabolic activities are needed to support the relentless cell division 
17 
 
and maintain the malignant properties of the cancer cells. Other than that, cancer cells 
undergo metabolic adaptation in order to promote their survival under conditions that 
kill normal cells (Cairns and Mak, 2016, DeBerardinis and Chandel, 2016).  
Cancer cell metabolism is a direct effect of the modification of intracellular pathways 
that are disrupted either by mutated oncogenes and tumor-suppressor genes or both. In a 
condition where the deoxyribonucleic acid (DNA) or genes of a cell are mutated, and the 
damaged cannot be repaired, the cells are no longer able to control the normal cell 
growth. The mutated oncogenic genes can directly result in the development of cancer 
(Hanahan and Weinberg, 2000, Jang et al., 2013). Current genomic sequencing have 
shown that cancer cells exhibit a wide range of genetic changes that disrupt the normal 
pathways, including cell growth and DNA replication (Copeland and Jenkins, 2009, 
Hudson et al., 2010). The altered energy metabolism of cancer cells, including 
mitochondrial, lipid and glucose are generally very similar which are to meet the 
bioenergetics requirements, biosynthetic demands and balance redox conditions of the 
cancer cells (Cairns and Mak, 2016, DeBerardinis and Chandel, 2016). Glucose 
metabolism, which involved high glycolysis and lactate formation is marked as a key 
metabolism that associates with aggressive tumor phenotypes (Granchi et al., 2014). 
1.3.1 Glucose metabolism in cancer cells 
In normal mammalian cells, glucose is the primary source and main fuel for cellular 
respiration, with glycolysis as a universal pathway for the catabolism of glucose. 
Glycolysis is the series of biochemical reactions that break down glucose into pyruvate 
and generate waste product, lactic acid (Chaudhry and Varacallo, 2019). In the presence 
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of oxygen, the pyruvate will undergo oxidative phosphorylation inside mitochondria to 
produce energy in the form of high-energy phosphate compound known as adenosine 
triphosphate (ATP). Whereas in the absence of oxygen, the pyruvate is reduced to lactate 
before being transported out of the cells (Figure 1.3) (Gatenby and Gillies, 2004, Schurr, 
2017). Under normal condition of glucose metabolism, about 70 % of ATP is 
synthesized by the oxidative phosphorylation (38 ATPs) and the rest by glycolysis (2 
ATPs) (Fadaka et al., 2017).  
Cancer cells require high amounts of energy in a short period of time for rapid 
proliferation and survival. Theoretically, cells undergo oxidative phosphorylation to 
generate high amounts of ATP rather than converting glucose into lactate which is far 
less efficient and produce less ATPs. However, cancer cells opt to generate ATP by 
glycolysis rather than oxidative phosphorylation (Hamanaka and Chandel, 2012). Most 
cancer cells exhibit high rate of aerobic glycolysis, which characterised as emerging 
hallmark in cancer metabolism (Xie et al., 2014b).  
Aerobic glycolysis is different to the anaerobic glycolysis that converts the glucose to 
lactate only in the absence of oxygen (Dashty, 2013, Jeff and Matthew, 2018). Cancer 
cells exhibit high aerobic glycolysis regardless of oxygen availability, even in presence 
of ample oxygen. In cancer cells, this event is characterized by elevation of glycolysis 





 Figure 1.3 Glucose metabolisms in mammalian cells 
The glucose enters the cells through glucose transporter (GLUT) and undergoes 
glycolysis process to produce pyruvate. Under aerobic conditions, pyruvate will enter 
the mitochondria to be oxidized to acetyl-CoA and produce 38 ATPs through oxidative 
phosphorylation. Under anaerobic conditions, pyruvate is reduced to lactate and excreted 
into extracellular space through monocarboxylate transporter (MCT). (Extracted from 







The phenomenon of high glycolysis in cancer cells can be visualized by using F-
deoxyglucose positron emission tomography (FDG-PET) in tumors. FDG-PET imaging 
from thousands of oncology patients have shown significant increased glucose uptake 
and variable secretion of lactate in human cancers compared to normal cells (Kostakoglu 
et al., 2003, Zhu et al., 2011). FDG-PET imaging also showed that increased glucose 
uptake correlated with poor prognosis and tumor aggressiveness (Gatenby and Gillies, 
2004, Caresia Aroztegui et al., 2017).  
1.3.2 Consequences and implications of aerobic glycolysis in cancer 
Increased glucose uptake in cancer cells may result from adaptive responses to a low 
oxygen level of tumor environment or known as hypoxia. During hypoxia, the oxidative 
phosphorylation will be inactive with mitochondrial dysfunction (Hu et al., 2012, Eales 
et al., 2016). Thus, cancer cells cannot obtain sufficient ATPs (Jang et al., 2013, 
Ganapathy-Kanniappan and Geschwind, 2013). Study by Otto Warburg observed that 
tumor cells continuously utilised glucose for glycolysis regardless of whether the cells 
are well-oxygenated or not  (Koppenol et al., 2011). The breakdown of glucose to lactate 
produces only 2 ATP, but the production is faster compared to oxidative 
phosphorylation. The rate of glycolysis and conversion of glucose to lactate in cancer 
cells is accelerated may be 100 times faster, thereby resulting in rapid ATP production 
(Pfeiffer et al., 2001, Locasale and Cantley, 2011) and other consequences for cancer 






Figure 1.4 The consequences and implications of aerobic glycolysis in cancer cells.  
Cancer cells tend to convert most glucose to lactate regardless of whether oxygen is 
present (aerobic glycolysis). Its benefits to the cancer cells in various ways, thus 





















Biosynthesis of macromolecules 
Increased glucose uptake in cancer cells is part of the metabolic adaptation for survival 
(Cairns and Mak, 2016). High glycolysis and increased glucose uptake may be 
beneficial to cancer cells through the production of glycolytic intermediates that will be 
used as precursors for many biosynthetic pathways. Biosynthetic pathways are essential 
aspect in cancer metabolism because they allow cells to generate macromolecules such 
as nucleotides, lipids, amino acids and NADPH, which are  required for rapid cell 
proliferation and tumor growth (Lunt and Vander Heiden, 2011). 
Angiogenesis and metastasis 
Hypoxia condition of the cancer cells drives the development of pre-malignant lesions 
that grows progressively away from the blood supply and upregulates the angiogenic 
factors (Semenza, 2012). Angiogenesis is the process by which tumor develops new 
vessels for blood supply. Initially, tumors can obtain oxygen and nutrient by simple 
diffusion, but as they grow excessively, they need to develop new blood vessels to fulfill 
the rapid requirement for growth, invasion and metastasis. The hypoxic conditions in 
cancer cells resulted in the upregulation of hypoxia-inducible factor apha 1 (HIF1α) 
expression. HIF1α overexpression is strongly associated with promoting tumor growth 
and metastasis through its role in initiating angiogenesis and regulating cellular 
metabolism  by activation of HIF1α target genes (Eales et al., 2016).  
Acidosis and therapeutic resistance 
High glycolysis rate in cancer cells results in increased lactate production, the-end 
product of glycolysis. Since the excess cytosolic acidification can inhibit the glycolysis 
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pathway of the cells, lactate is then excreted out from the cells through monocarboxylate 
transporters (MCT) (Bonen, 2001, Halestrap and Wilson, 2012).  A constitutive 
production of lactate will generate an acute cytosolic acidification and lower the 
extracellular pH of the cells, approaching value 6.0. Studies have shown that under 
acidic environment, normal cells are unable to grow due to the lack of mechanism to 
adapt to the pH imbalance (Raghunand et al., 2003, Swietach, 2019). However, cancer 
cells are able to proliferate continuously regardless of imbalanced pH. The evolutionary 
potential and adaptation of the cells towards the acidosis accelerates the malignant 
progression and acquire a resistance to the therapeutic strategies. Moreover, the acidosis 
itself can be a mutagenic factor to the nearby normal cells (Gatenby and Gillies, 2004, 
Gharia et al., 2018). 
ROS Production and redox balance 
Reactive oxygen species (ROS) are heterogeneous compounds of highly reactive 
chemical species containing oxygen. ROS are produced as a natural by-product of many 
metabolic pathways such as oxidative phosphorylation, oxygen metabolism and 
NADP/NADPH oxidative functions. Due to their high reactivity characteristics, their 
effects are unspecific, that can be either beneficial or detrimental (Cairns et al., 2011). 
At high metabolic rates of cancer cells, the ROS production is increased, resulting a shift 
in the redox balance that can promote even higher growth rate and cancer progression. 
Thus, the accumulation of ROS for up to the toxic levels will induce severe oxidative 
stress and trigger the cell death or senescence (Reuter et al., 2010). As a defense 
mechanism to survive, cancer cells must up-regulate antioxidant mechanism that can 
scavenge the ROS (Anastasiou et al., 2011, Cairns et al., 2011).  
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In cancer cells, HIFs mediated the stimulation of glycolysis in order to inhibit further 
mitochondrial production of ROS, and activate reducing system that can scavenge these 
ROS. Increased glucose uptake is frequently observed during the conditions of oxidative 
stress. Studies showed that high ROS production induces glucose uptake, which 
suggested the role of glucose in ROS scavenging (Merry et al., 2010, Pinheiro et al., 
2010, Andrisse et al., 2014).  
The activation of pentose phosphate pathway (PPP) (a metabolic pathway parallel to the 
glycolysis) will generate NADPH to reduce the glutathione (GSH), which is an 
antioxidant that can detoxify the ROS. Since accumulation of ROS can shut down the 
cell metabolism pathway, the flow of glucose to PPP is critical for cancer survival to 
produce enough GSH in order to detoxify the excess ROS (Anastasiou et al., 2011). 
1.3.3 Key players in glucose metabolism of cancer cells 
Glucose transporters (GLUTs) 
The first rate-limiting step of glucose metabolism is the transport of glucose across the 
plasma membrane mediated by facilitative glucose transporters (GLUTs) proteins. 
GLUTs permit the energy independent transport of glucose across the cell membrane 
(Macheda et al., 2005, Adekola et al., 2012). There are 14 members of the mammalian 
GLUTs family that have been identified and each of the members possesses different 
affinities for glucose or other hexoses.  For example, GLUT1, GLUT3 and GLUT4 have 
high affinity for glucose and allowing transport of glucose at a high rate under normal 
physiological environment (Navale and Paranjape, 2016). Meanwhile, GLUT2 has high 
affinity and mediated fructose uptake in the cells (Barron et al., 2016). 
